MD, University of Maryland
Residency, Internal Medicine
Boston University Medical Center
University of Virginia Health System
Mount Sinai Hospital
Advanced Hepatology Fellowship Grant
American Association of Liver Diseases
Tau Beta Pi
Johns Hopkins University
Engineering Honor Society
Research and Excellence Provost's Award for Undergraduate
Johns Hopkins University, Baltimore, Maryland
Westinghouse Science Talent Search Semifinalist
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib
The purpose of this study is to find out whether ramucirumab can help patients with liver cancer. Ramucirumab is an experimental drug because it is still being tested and not yet approved to treat liver cancer. However, the FDA has allowed the use of this drug for res...
A Phase 2b Dose-Ranging Randomized Double-Blind Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624 a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2) in Subjects with Advanced Liver Fibrosis but not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis
The purpose of this study is to see if an experimental drug named GS-6624 works for the treatment of advanced fibrosis of the liver due to Non-Alcoholic Steatohepatitis (NASH). We are studying 2 different doses of GS-6624 in this study, because we do not know what the right dose ...
A Phase IIb, double blind randomized, controlled clinical trial, to evaluate the efficacy and safety of two Aramchol doses versus placebo in patients with Non-Alcoholic Steatohepatitis (NASH)
The purpose of this study is to test a new investigational drug called Aramchol. The study will be a multinational, multicenter trial to compare the efficacy, tolerability and safety of Aramchol tablets 400 mg and 600 mg to placebo tablets, in 240 NASH subjects who also suffer fr...
Chang CY, Hernandez-Prera JC, Roayaie S, Schwartz M, Thung SN. Changing epidemiology of hepatocellular adenoma in the United States: review of the literature. International journal of hepatology 2013; 2013.
Martin P, Chang C. Update on the United States Hepatitis B Treatment Algorithm. Current Hepatitis Reports 2007;.
Chang C, Singal A, Emre S, Schiano T, Lookstein R, Ganeshan S. Successful Use of Splenic Artery Embolization to Relieve Tense Ascites Following Liver Transplantation in a Patient with Budd Chiari Syndrome, Paroxysmal Nocturnal Hemoglobinuria, and Portal Vein Thrombosis: A Case Report. Liver Transplantation 2007; 13(11): 1532-1537.
Tuyama AC, Chang CY. Non-alcoholic fatty liver disease. Journal of diabetes 2012 Sep; 4(3).
Chang CY, Martin P, Fotiadu A, Hytiroglou P. A patient with chronic hepatitis B and regression of fibrosis during treatment. Seminars in liver disease 2010 Aug; 30(3).
Schiano T, Chang C. Drug Hepatototoxicity Update. Alimentary Pharmacology and Therapeutics 2007; 25(10): 1135-1151.
Ward SC, Chang CY, Peng L, Liu LU. Patient with hepatitis B and alcoholic liver disease before and after liver transplantation. Seminars in liver disease 2009 May; 29(2).
Caldwell S, Macik G, Chang C. Recombinant Activated Factor VII (rFVIIa) as a Hemostatic Agent in Liver Disease: A Break from Convention in Need of Controlled Trials. Hepatology 2004; 39(3): 592-598.
Tan HH, Chang CY, Martin P. Acetaminophen hepatotoxicity: current management. The Mount Sinai journal of medicine, New York 2009 Feb; 76(1).
Caldwell S, Krugner-Higby L, Nakamoto R, Chang C. The Mitochondria in Non-Alcoholic Fatty Liver Disease. Clinics in Liver Disease 2004; 8(3): 595-617.
Chang C, Argo C, Caldwell S, Al-Osaimi A. Antioxidant Therapy in Non-Alcoholic Fatty Liver Disease. J Clin Gastroenterol 2005; 39(suppl 4).
Caldwell S, Chang C, Nakamoto R, Krugner-Higby L. Enlarged hepatocytes in NAFLD examined with osmium fixation: does microsteatosis underlie cellular ballooning in NASH?. Clinics in Liver Disease 2004; 8(3): 595-617.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Chang during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.